NASDAQ$BVS
Bioventus Inc - A · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Bioventus reported second quarter financial results and introduced full year 2023 financial guidance.
Bioventus reported net sales of $137.1 million, a decrease of 2.3% year-over-year. Net loss from continuing operations was $4.7 million, and adjusted EBITDA increased 26.1% to $28.2 million. The company also closed the sale of its Wound Business for $31.0 million and repaid $60.3 million of debt.
- Net sales decreased by 2.3% year-over-year to $137.1 million.
- Net loss from continuing operations was $4.7 million, an improvement from the prior-year period.
- Adjusted EBITDA increased by 26.1% to $28.2 million.
- The company closed the sale of its Wound Business, generating $31.0 million in net proceeds.
Headline financials
Revenue & EPS history
Bioventus · Revenue · Quarterly
$137M
Forward guidance
For the twelve months ending December 31, 2023, the company expects net sales of $490 million to $505 million, adjusted EBITDA of $75 million to $80 million, and Non-GAAP EPS of ($0.24) to ($0.20).
Tailwinds
- Net sales of $490 million to $505 million
- Adjusted EBITDA of $75 million to $80 million
Headwinds
- Non-GAAP EPS of ($0.24) to ($0.20)
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+2.1%
Avg return
Earnings day
+5.6%
Avg return
5 days after
+13.1%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+26.0%
Q1 2024
Best reaction
-39.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.2% | -4.6% | -15.4% | |
| Q4 2025 | +7.4% | +4.6% | +5.9% | |
| Q3 2025 | +15.1% | +13.6% | +16.2% | |
| Q1 2025 | -12.0% | -5.0% | -7.4% | |
| Q4 2024 | +23.3% | +9.7% | -13.6% | |
| Q3 2024 | -17.7% | -13.8% | -15.1% | |
| Q2 2024 | +19.2% | +21.2% | +54.3% | |
| Q1 2024 | +26.0% | +35.0% | +70.0% | |
| Q4 2023 | -0.4% | +2.6% | -9.4% | |
| Q3 2023 | +6.0% | -2.1% | +42.1% | |
| Q2 2023 | +20.3% | +32.9% | -2.6% | |
| Q1 2023 | +6.5% | +58.5% | +195.9% | |
| Q4 2022 | -6.6% | +2.5% | -16.5% | |
| Q3 2022 | -39.9% | -42.7% | -18.9% | |
| Q2 2022 | +4.8% | +3.9% | -6.4% | |
| Q1 2022 | -9.1% | +4.5% | +12.5% | |
| Q4 2021 | +0.8% | -3.0% | -4.0% | |
| Q3 2021 | -0.5% | -4.5% | -18.7% | |
| Q2 2021 | +1.7% | +0.3% | -0.7% | |
| Q1 2021 | +1.0% | +3.3% | +17.0% | |
| Q4 2020 | -4.8% | -0.4% | -9.1% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro